Xeris Pharmaceuticals Inc. (XERS) Tops Q3 EPS by 3c

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q3 EPS of ($0.16), $0.03 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $29.6 million versus the consensus estimate of $30.29 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Credo Technology pops 3.5% as Evercore initiates with monster $325 price target
• Stifel Reiterates Buy Rating on FedEx (FDX) Ahead of Q4 Earnings